Menu Search
Equities

Swedish Orphan Biovitrum AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
B6E:MUN

Swedish Orphan Biovitrum AB (publ)

Actions
  • Price (EUR)35.82
  • Today's Change1.02 / 2.93%
  • Shares traded--
  • 1 Year change+23.52%
  • Beta0.0700
Data delayed at least 15 minutes, as of Feb 06 2026 08:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.

  • Revenue in SEK (TTM)28.24bn
  • Net income in SEK478.00m
  • Incorporated1939
  • Employees1.89k
  • Location
    Swedish Orphan Biovitrum AB (publ)Norra Stationsgatan 93ASTOCKHOLM 112 76SwedenSWE
  • Phone+46 86972000
  • Websitehttps://www.sobi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SOBI:STO since
announced		Transaction
value
Pharma Investments SAAnnounced09 Oct 202509 Oct 2025Announced26.78%--
Pint Pharma International LtdDeal completed16 Sep 202516 Sep 2025Deal completed44.98%--
Data delayed at least 15 minutes, as of Feb 06 2026 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.